{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:26Z","timestamp":1790983106080,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an established first-line treatment for non-small cell lung cancer (NSCLC) patients with sensitizing mutations because of their remarkable efficacy and favorable tolerability profiles. However, rare and severe adverse reactions during their application require attention. Cases of diabetic ketoacidosis (DKA) associated with EGFR-TKI therapy have seldom been reported and the underlying mechanism remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present the case of a 64-year-old female patient with immune checkpoint inhibitor-induced diabetes mellitus (ICI-DM) on aumolertinib (a third-generation EGFR-TKI, 110 mg daily) for the treatment of NSCLC admitted to the hospital with frequent episodes of DKA. Owing to a recurrent DKA episode following a reduced dosage (55 mg daily), aumolertinib was suspended permanently. After full recovery from the DKA, the patient was switched to osimertinib (80 mg daily). Insulin resistance in the patient was assessed using a hyperinsulinemic-euglycemic clamp. She was maintained on standard-dose osimertinib and insulin therapy after discharge and remained asymptomatic during the outpatient follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Owing to the protocol-defined strict inclusion and exclusion criteria, some potentially serious adverse reactions may not be as commonly observed in clinical trial settings. Aumolertinib-induced exacerbation of insulin resistance can precipitate a spectrum of hyperglycemia, ranging from mild elevations to severe DKA, which highlights the necessity of blood glucose monitoring throughout the treatment course. By assessing a patient\u2019s tolerance profile for EGFR-TKIs-aggravated insulin resistance using the insulin clamp technique, clinicians can optimize antineoplastic regimens, such as switching from aumolertinib to osimertinib in this case.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1862643","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:25:32Z","timestamp":1785471932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Diabetic ketoacidosis following EGFR-TKIs therapy via aggravated insulin resistance"],"prefix":"10.3389","volume":"16","author":[{"given":"Shengjie","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Diabetic Foot Multidisciplinary Treatment Center, Honghui Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01029-7","article-title":"Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer","volume":"22","author":"Tang","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04050-5","article-title":"Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus","volume":"87","author":"Kani","year":"2025","journal-title":"Endocrine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/endocrines7020018","article-title":"Immune checkpoint inhibitor-associated diabetes mellitus: Future perspectives and emerging therapies","volume":"7","author":"Karavendzas","year":"2026","journal-title":"Endocrines"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1679751","article-title":"Immune checkpoint inhibitor-associated diabetes mellitus: mechanisms, clinical manifestations, and management strategies","volume":"16","author":"Chen","year":"2025","journal-title":"Front Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14362","article-title":"Immune checkpoint inhibitor\u2010related type 1 diabetes incidence, risk, and survival association","volume":"16","author":"Kamitani","year":"2025","journal-title":"J Diabetes Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2014.09.08","article-title":"Update on third-generation EGFR tyrosine kinase inhibitors","volume":"3","author":"Gray","year":"2014","journal-title":"Trans Lung Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2015.10.01","article-title":"Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance","volume":"4","author":"Villadolid","year":"2015","journal-title":"Trans Lung Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02641","article-title":"AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/bmj.39237.661111.80","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: Updated post-National Medical Products Administration approval results from the APOLLO registrational trial","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: A multicenter, open-label, phase 1 trial","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.11648\/j.ijpc.20210706.14","article-title":"Classifying causality of an adverse drug reaction: Naranjo algorithm","volume":"7","author":"Bereda","year":"2021","journal-title":"Int J Pharm Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-199010000-00003","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/dmr.5610050501","article-title":"Assessment of insulin sensitivity in vivo","volume":"6","author":"Richard","year":"1985","journal-title":"Endocr Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16159","article-title":"Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis","volume":"27","author":"Mather","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor\u2013associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.63.p201","article-title":"Acquired generalized lipodystrophy: A new cause of anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-sitc2022.1252","article-title":"1252\u2005Immune-checkpoint inhibitor induced autoimmune diabetes is a heterogeneous disease with distinct clinical and immune phenotypes","author":"Ruiz-Esteves","year":"2022","journal-title":"Regular Young Investigator Award Abstracts"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B23","article-title":"Application of extended hyperinsulinemic euglycemic clamp in the assessment of insulin sensitivity in obese individuals with glucose intolerance","volume":"28","author":"Bao","year":"2006","journal-title":"Acta Academiae Medicinae Sinicae"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1038\/s41467-022-32348-3","article-title":"EGFR-mediated activation of adipose tissue macrophages promotes obesity and insulin resistance","volume":"13","author":"Cao","year":"2022","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0519","article-title":"Hyperglycemia associated with targeted oncologic treatment: Mechanisms and management","volume":"21","author":"Goldman","year":"2016","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1862643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:25:37Z","timestamp":1785471937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1862643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1862643"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1862643","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1862643"}}